Run Du Group: Obtaining Approval for Listing Application of Hydrochloric Deoxymethylnaltrexone Chemical Raw Material

Run Du Co., Ltd. announced that the company recently received the approval notice for the listing application of the chemical raw material drug hydrochloride mefuxamine issued by the National Medical Products Administration. The company submitted the listing application in January 2024 and it was accepted, and it was approved in April 2026. This product is the raw material of the company's Class 1 new drug hydrochloride mefuxamine injection, which is used for isotope myocardial perfusion imaging. The approval will accelerate the full industry chain production and commercialization of the injection, and it is of great significance for the company's research and development system construction, long-term benefit for enhancing its competitiveness in the cardiovascular field, and short-term performance will not be significantly affected.